scientific Advisory Board
Scientific Advisory Board
Dr. James E. Sanders, DVM, PhD, DABT

Is President of New Entity Consulting, Inc. providing to clients support in regulatory toxicology. Has over thirty years experience in Toxicology and Veterinary Pathology in the pharmaceutical industry. Employed from1978 to 1981 as a staff pathologist in the U.S. Army at Walter Reed Army Institute of Research and from 1981 to 1987 as a Veterinary Pathologist at Merck, Sharp and Dohme. Joined Rhône-Poulenc Rorer as Director of Toxicology in 1987 and continued through mergers (Aventis, Sanofi Aventis) until 2005. Here, as Global Head of Toxicology, had worldwide responsibilities for designing and implementing the nonclinical toxicology and safety pharmacology testing of all drug candidates developed by the company. Was responsible for the preparation of the nonclinical sections for all INDs, NDAs, CTXs, and MAAs and for the communications with government Health Authorities globally. From 2005 to 2007 was Senior Director at Johnson & Johnson, directing development of pharmaceuticals from early development through NDA and MAA approval including government Health Authority interface. In these positions, has represented his company externally in forums and working parties such as the CPMP’s SWP, DIA, ILSI, Toxicology Forum, ICH and PhRMA. Attended Ohio State University gaining a DVM, an MS in Pharmacology and a PhD in toxicology. Is certified by the American Board of Toxicology and is a member of the SOT, and the Society of Toxicological Pathologists.


Dr. Cheryl London, DVM, PhD

Cheryl London is a Professor at the Ohio State University College of Veterinary Medicine, Department of Veterinary Biosciences. She holds the Thekla R. and Donald B. Shackelford Professorship in Canine Medicine, is Director of the Clinical Trials Office, College of Veterinary Medicine and Director of Translational Therapeutics at the Center for Clinical and Translational Sciences, OSU College of Medicine. Before coming to Ohio State in 2005, she was an Assistant Professor in the Department of Surgical and Radiological Sciences at the University of California Davis. Dr. London earned her DVM at Tufts University, completed her Residency in Medical Oncology at the University of Wisconsin-Madison, and her PhD at Harvard University, where she was also postdoctoral fellow in the Department of Pathology. Her research interests center primarily on targeted therapeutics and translational/comparative oncology.


Dr. T. S. Ganesan M.D, Ph.D

Dr. T.S.Ganesan graduated 'Summa cum Laude' from Jawaharlal Institute of Medical Education and Research, Pondicherry, India and completed his MBBS and MD in Internal medicine followed by Senior Residency. He completed his training in Medical Oncology at St. Bartholomew's Hospital, London. His doctorate was on Philadelphia chromosome positive leukemias that was awarded by the University of London. He was subsequently appointed as Consultant Medical Oncologist at Churchill Hospital, Oxford and established a laboratory as Clinical Scientist at the Weatherall Institute of Molecular Medicine, Oxford. After 15 years at Oxford he was appointed as Chairman, Cancer Institute and Institute of Molecular Medicine at Amrita Institute of Medical Sciences, Cochin, India towards the end of 2005. His research interests have been on cancer genetics and signal transduction, in addition to clinical trials. The research in UK was supported initially by the Imperial Cancer Research Fund and subsequently by Cancer Research UK. In India, the research is supported by Department of Biotechnology and Indian Council of Medical Research. He has been awarded the Clinical Excellence award in UK during his tenure there. He has over 100 papers to his credit in international journals.


Dr. Dhanapalan Nagarathnam Ph.D

Dr. Nagarathnam is currently the President of DNSK International, llc. Hamden, CT, where he is focused on collaborative drug discovery projects with biotechs and leading academic institutions in a variety of therapeutic areas including multiple cancer indications, diabetes, autoimmune disorders, HCV, anti-bacterial, inflammatory bowel disease (IBD), etc. Prior to this, Dr. Nagarathnam was the Director of Medicinal Chemistry at Pharmasset, Princeton, NJ, wherein he directed the HCV drug discovery projects and played a key role in selecting three liver-targeted clinical candidates and the most advanced candidate is in Phase-III human trials, and the company was later acquired by Gilead in 2012. Dr. Nagarathnam also worked as Principal Research Scientist-II at Bayer HealthCare, West Haven, CT, in multiple oncology, diabetes, obesity and osteoporosis projects and Synaptic Pharmaceutical Corporation (currently Lundbeck), Paramus, NJ on multiple human GPCR-targeted projects targeting BPH, pain, obesity, etc. In the Synaptic/Merck collaboration project he contributed to nomination of two alpha-1a adrenoceptor selective candidates for the treatment of Benign Prostatic Hyperplasia (BPH).

Dr. Nagarathnam has over 25 years of experience in pharmaceutical industry and this includes leadership role in project management, medicinal chemistry, combinatorial chemistry, high-throughput synthesis, lead generation, lead optimization, process research, production, and business development.

Dr. Nagarathnam obtained his Ph. D. in Organic Chemistry from the University of Madras, India and conducted postdoctoral research in Medicinal Chemistry at University of California, Purdue University, and University of Illinois and process research at Malti-Chem Research Center. Overall, Nagarathnam is an inventor on over 50 issued patents/patent applications, and an author of over 75 peer-reviewed publications in leading journals and conference presentations